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g.2012.1Abstract Endometriosis is a chronic, inﬂammatory, estrogen dependent disease that affects up to
10% of all women of fertile age. It is characterized by the presence and proliferation of functional
endometrial glands and stroma outside the uterine cavity. The aim of this study was to assess
whether intron 4 (TTTA)n repeat and TCT deletion/insertion polymorphisms of CYP19 gene are
associated with endometriosis in northern Iran. This study involved 110 patients with endometriosis
and 200 healthy controls, who were genotyped for (TTTA) repeats in the fourth intron of the
CYP19 gene. Genomic DNA from patients and controls was genotyped by polymerase chain reac-
tion (PCR). A total of eight alleles were observed in our study population, ranging from 7 repeats to
13 repeats. (TTTA) repeat lengths of 69 were classiﬁed as short (S), and thoseP10 were classiﬁed
as long (L). Compared to women who possessed the S/S genotype, those who carried L/L (OR,
5.56; 95% CI, 3.33–9.29) had signiﬁcantly increased risk of endometriosis. There was a signiﬁcant
trend between L/L genotype and higher stage of endometriosis (P< 0.001). In conclusion, a signif-
icant association was identiﬁed between endometriosis and the CYP19 gene polymorphism, with
endometriosis having longer CYP19 repeat lengths than control subjects. The strong association
of CYP19 gene polymorphism with high-stage endometriosis suggests that CYP19 may have a
prognostic implication.
 2012 Ain Shams University. Production and hosting by Elsevier B.V. All rights reserved.rtment of Biology, Faculty of
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0.0021. Introduction
Endometriosis is characterized by the presence of uterine tis-
sues (endometrial glands and stroma) in areas other than the
uterus, such as the pelvic ﬂoor or around the fallopian tubes
and ovaries [1]. The prevalence in women without symptoms
is 2–50%, depending on the diagnostic criteria used and the
populations studied [2]. The incidence is 40–60% in women
with dysmenorrhea and 20–30% in women with subfertility.
The severity of symptoms and the probability of diagnosis in-
crease with age. Endometriosis is associated with increasedier B.V. All rights reserved.
166 H. Saber et al.overall cancer risk, with particular elevation of ovarian cancer
risk [3]. Two principal explanations for the development of
endometriosis are retrograde menstruation and coelomic meta-
plasia hypothesis. The most common theory is retrograde men-
struation, which consists of the reﬂux of menstrual ﬂuid
through the Fallopian tubes to the abdominal cavity [4].
It was widely accepted that both genetic and environmental
factors may be involved in the etiology of endometriosis. Can-
didate genes speciﬁcally studied for association or linkage with
endometriosis includes galactose-1-phosphate uridyl transfer-
ase [5], phase I and II detoxiﬁcation genes [6], adhesion
ICAM-1 [7] and VEGF [8,9].
The CYP19 gene encodes aromatase that is the key enzyme
for the terminal step of estrogen biosynthesis by converting
19-carbon steroids (testosterone and androstenedione) to
18-carbon estrogen (estradiol and estrone). Aromatase is
expressed in ovarian, placental, testicular, adipose, bone and
brain tissues [10].The CYP19 gene is located in the chromo-
some 15q21.2 region and is comprised of a 30 kb coding region
and a 93 kb regulatory region. Tissue speciﬁcity is regulated by
the use of nine alternate untranslated ﬁrst exons located in the
large 93 kb gene regulatory unit. It is reported that several sin-
gle nucleotide polymorphisms (SNPs) of the CYP19 gene were
associated with variations in serum androgen concentrations
among women, both within and between racial/ethnic groups.
The CYP19 gene has a tetranucleotide repeat polymorphism
(TTTA)n=7–13 in intron 4, about 80-bp downstream of intron
4, with the 7 and 11 repeats being most common [11]. There is
also a 3-bp deletion 50-bp upstream of the repeat [12]. The
deletion is found in those with 7 repeats, generating 2 alleles:
7 repeats with the 3-bp deletion; and 7 repeats without the
deletion. This polymorphism has been associated with the
hyperandrogenic phenotype of polycystic ovary syndrome
[13]. It has also been related to increased risk for the develop-
ment of various estrogen dependent diseases in women such as
breast and lung cancers and osteoporosis [14–18]. However,
the molecular mechanisms responsible for changes in aroma-
tase activity and susceptibility in estrogen-dependent diseases
are unclear.
Endometriosis is an estrogen-dependent disease. We
hypothesized that the longer alleles of CYP19 would be more
frequent and preferentially more active among the patients
with endometriosis than the controls.2. Subjects and methods
2.1. Characteristics of subjects
All subjects were Iranian, unrelated, and residents of the Gui-
lan province in northern Iran. 110 patients with endometriosis
diagnosed by laparoscopy and classiﬁed by histological criteria
according to the Revised American Society for Reproductive
Medicine were selected. For the control group, 200 fertile wo-
men who had undergone tubal ligation were included in this
study. Clinical information on patients was collected from clin-
ical notes, including lesion size, location, stage of disease, drug
treatment and fertility. The control patient was conﬁrmed to
have no endometriotic or other pathological lesions in the pel-
vic cavity. Written consent of the patients was obtained
according to the Declaration of Helsinki. After cases andcontrols were identiﬁed, whole blood samples of 1 ml were
collected from each subject in heparin-containing tubes.
The samples were stored at 4 C and centrifuged at 2800 rpm
for at least 10 min within the next 24 h. The three independent
fractions were isolated and stored at 70 C until analysis.
Laboratory personnel blinded to the case-control status of
the samples performed all genotyping, and each plate
included blinded replicate samples for quality control pur-
poses. The replicate samples were 100% concordant for all
genotypes.
2.2. DNA isolation
Genomic DNA was isolated from peripheral leukocytes by
DNG TM-Plus Kit (Cinnagen, Iran). DNA was dissolved in
TE buffer [10 mM Tris (PH 7.8), 1 mM EDTA].The DNA
integrity was certiﬁed by electrophoresis on 2% agarose gel
stained by ethidium bromide (0.5 mg/ml) and visualized with
a Gel Documentation System (BioRad). The ﬁnal preparation
was stored at- 20 C and used as a template for polymerase
chain reaction (PCR).
2.3. (TTTA)n repeat length determinations
The CYP19 (TTTA)n repeat was typed by PCR ampliﬁcation
of genomic DNA in the presence of a forward primer;
5’-GCAGGTACTTAGTTAGCTAC-3’ and reverse primer;
5’-TTACAGTGAGCCAAGGTCGT-3’. The primers were
designed in our laboratory using Oligo7 software. The PCR
reaction contained 1 mM of each primer, 0.5 U Taq polymer-
ase, 200 mM dNTP mixture, and 2 mM MgCl2 in addition to
test DNA, made upto a ﬁnal volume of 25 ll.
PCRs were performed in the MJ MiniTM Gradient Thermal
Cycler (Bio-Rad), which was programed as follows: initial
denaturing at 94 C for 7 min, followed by 30 cycles of 94 C
for 1 min, 55 C for 1 min, 72 C for 1 min, and ﬁnally 72 C
for 10 min. The PCR products were visualized on 6% poly-
acrylamide gel by silver staining. The size of PCR fragment
sizes was assigned by comparison to a sequence-veriﬁed frag-
ment ladder by two independent readers. The products were
168–195-bp in respect of the number of TTTA repeats.
2.4. Statistical analysis
Statistical analysis was performed using the v2 test and the
Med Calc version 9.3. Strength of association between endo-
metriosis and alleles of the TTTA repeat and TCT deletion/
insertion polymorphisms of CYP19 were estimated using odds
ratios (OR) and 95% conﬁdence intervals (CI). Statistical sig-
niﬁcance was deﬁned as P 6 0.05.
3. Results
The age of the patients ranged from 21 to 36 years. There was
no signiﬁcant difference in terms of distribution of age between
the cases and controls (P= 0.02). All patients were infertile
[primary infertility in 87 (79%) and secondary infertility in
23 (21%)], with 94 (85%) of 110 complaining of chronic pelvic
pain, 65 (59.1%) having dyspareunia. Eighty-seven (79.1%)
women had dysmenorrhea (Table 1). Signiﬁcant differences
Table 1 General characteristics of the study population.
No. of patients 110
Median age in years 32
Symptoms
Chronic pelvic pain 94 (85%)
Dysmenorrhea 87 (79.1%)
Dyspaurnia 65 (59.1%)
Primary infertility 87 (79%)
Secondary infertility 23 (21%)
Stage of diseasea
Stage I–II 43
Stage III–IV 67
a According to the Revised American Fertility Society staging
system.
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symptoms (P< 0.001).
3.1. CYP19 (TTTA)n polymorphism
In the present study, eight different TTTA alleles were identi-
ﬁed by size. These alleles contained a sequence ranging from 7
(168-bp) to 13 TTTA repeats (195-bp). The global allele fre-
quencies of the CYP19 (TTTA) repeat polymorphism in the
healthy control women and patients with endometriosis are
illustrated in Fig. 1. The shortest allele of 168-bp carried seven
TTTA repeats and a 3-bp deletion 50-bp upstream of the
repetitive sequence, and we identiﬁed it as (TTTA)7 +
delTCT; the allele of 171-bp had the same number of TTTA
repeats but no TCT deletion, so we deﬁned it as (TTTA)7.
The next most-frequent allele of 187-bp had 11 (TTTA)
repeats and a TCT insertion and we deﬁned it as (TTTA)11.
TTTA repeat lengths of 69 were classiﬁed as short (S), and
those P10 were classiﬁed as long (L). Proportions of the
CYP19 (TTTA)n alleles in both groups were signiﬁcantly dif-
ferent (Table 2 and Fig. 1).
Because women have two CYP19 gene alleles, homozygos-
ity was deﬁned as two repeats of the same length. Different
lengths for two repeats indicated heterozygosity. Patients and
control subjects were separated into subgroups comprising
those with two short alleles (S/S), those with one short and
one long allele (S/L), and those with both long alleles (L/L).
Compared to women who possessed the TTTA S/S genotype,0
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Figure 1 Frequency of (TTTA) rethose who carried L/L genotype (OR, 5.56; 95% CI, 3.33–9.29)
had signiﬁcantly increased risk of endometriosis (Table 2).
3.2. Association between CYP19 (TTTA) n repeat
polymorphism and stages of endometriosis
To evaluate whether the TTTA polymorphism in CYP19 is
associated with the severity of endometriosis, participants were
categorized into three groups according to the revised Ameri-
can Society for Reproductive Medicine: controls, stage I–II
and stage III–IV (Table 3). Among 110 women with endome-
triosis, 43 and 67 women were classiﬁed as stage I–II and stage
III–IV, respectively. A signiﬁcant difference in the distribution
of genotypes for the CYP19 polymorphism and stages of dis-
ease were found. There was also a signiﬁcant trend between
the L/L genotype and stage of endometriosis (P< 0.001).
4. Discussion
Endometriosis is thought to be estrogen-dependent in vivo for
several reasons. Endometriosis does not occur before menar-
che and symptoms abate after menopause [19]. Estrogen ago-
nists worsen lesions and antagonists are used to treat them
[20]. Markers of increased serum estrogen levels (high body
fat, low waist:hip ratio) are linked to increased disease risk,
while anti-estrogenic inﬂuences (smoking, vigorous exercise)
are associated with decreased risk [21]. Endometriosis implants
synthesize large quantities of estradiol (E2) locally during the
secretary phase than the dose endometrium from women with-
out the disease [22]. Aromatase, which catalyzes the ﬁnal step
in estrogen (E1) and E2 biosynthesis, is expressed in endome-
triotic stroma but not in the normal endometrium [23].
Changes in aromatase biosynthesis are usually preceded by
changes in its gene transcription and mRNA level. Gene vari-
ability could contribute to the level of the aromatase biosyn-
thesis. A polymorphic tetranucleotide repeat (TTTA)n has
been identiﬁed in intron 4 about 80 nucleotides downstream
of exon 4 in the CYP19 gene near the intron/exon border. This
close proximity to the intron/exon suggests a possible role for
these tetranucleotide repeats in the determination of splicing
sites [24]. Longer repeats (which various studies deﬁne as be-
tween 7 and 10 repeats) have been associated with higher levels
of circulating estrogen levels in older men [16] and women [17].
Studies of hormone-related cancers report conﬂicting ﬁndings
with regard to this polymorphism and cancer risk, with10 11 12 13
) repeats
f (TTTA) repeats
Controls
Patients
peats in the studied population.
Table 3 CYP19(TTTA)n genotype frequencies in different
stages of endometriosis.
Genotype Stage I–II n (%) Stage III–IV n (%)
S/S 13 (11.8) 5 (4.5)
L/S 9 (8.2) 11 (10)
L/L 21 (19.1) 51 (46.4)
v2 = 11.57, P= 0.003.
Table 2 Frequency of CYP19 (TTTA)n alleles and genotypes in the studied populations.
Allele/genotype Endometriosis Controls OR (95% CI) P value
n (%) n (%)
Short 84 (38.2) 314 (78.5) 1.00 (reference)
Long 136 (61.8) 86 (21.5) 5.91 (4.11–8.48) <0.0001***
S/S 18 (16.4) 82 (41) 0.28 (0.15–0.50) a <0.001**
S/L 28 (25.4) 78 (39) 0.53 (0.31–0.89) b <0.01*
L/L 64 (58.2) 40 (20) 5.56 (3.33–9.29) c <0.0001***
a Calculation was performed following a dominant genotype model for S/S versus S/L and L/L.
b Calculation was performed for S/L versus S/S and S/L.
c Calculation was performed following a recessive genotype model for L/L versus S/L and S/S.
* P< 0.01.
** P< 0.001.
*** P< 0.0001.
168 H. Saber et al.inconsistent ﬁndings reported for breast [25], prostate [26] and
endometrial cancer [18].
It has been demonstrated that vascular endothelial growth
factor (VEGF), GSTM1 and intercellular adhesion molecule-
1 (ICAM-1) gene polymorphism are associated with the risk
of endometriosis [27–29]. Berstein et al. noted an increased
estrogen biosynthesis (the highest aromatase activity) in endo-
metrial tumors from (TTTA)11/(TTTA)11 and (TTTA)11/
(TTTA)12 genotype carriers [15]. The results are compatible
with those reported by Gennari et al. in skin ﬁbroblasts [16].
So far, there are only few reports concerning the relationship
of CYP19 genetic polymorphism with endometriosis. To the
best of our knowledge, this is the ﬁrst study on Iranian women
to examine the association of CYP19 polymorphism with
endometriosis. In this study, we found that the alleles contain-
ing 11 and 12 TTTA repeats were over-represented in the pa-
tients with endometriosis. Our results support an association
between long CYP19 alleles and an increased risk for endome-
triosis in Iranian women. When comparing patients with dif-
ferent stages of endometriosis, we found a trend toward
higher frequency of longer alleles in patients with stages III
and IV (19.1 vs 46.4%; P= 0.003). Arvanitis et al. found that
the allele 10 TTTA repeats were more prevalent in patients
with endometriosis (OR, 4.99; 95% 95% CI, 1.351 to 18.436)
[30]. However, in a study by Kado et al., the authors found
no association between the allele frequency of the TTTA re-
peat polymorphism and endometriosis [31]. A study of Korean
women reported that the frequency of the higher risk alleles of
the CYP19 gene was not higher in endometriosis patients than
in controls. They also found that the risk of endometriosis also
did not increase signiﬁcantly with the number of higher risk al-
leles of the CYP19 gene [32]. The lack of consistent association
of the CYP19 (TTTA) polymorphism with endometriosis riskmay be due to differences of allele frequencies between ethnic
groups, genetic heterogeneity in the pathogenesis of endome-
triosis, and different environmental factors.
In conclusion, this pilot study carried out in Iran focused
on 110 women with endometriosis. A strong association be-
tween long CYP19 alleles and endometriosis was conﬁrmed
overall. Our ﬁndings also suggest that CYP19 (TTTA)n
genetic polymorphism is associated with advanced-stage endo-
metriosis in Iranian women. Further studies in larger popula-
tions are required to conﬁrm the implication of the (TTTA)n
repeat polymorphism in the intron 4 of the CYP19 gene in
the pathogenesis of endometriosis.Acknowledgements
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